We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Treatments to Raise HDL Cholesterol May Not Reduce Heart Attack Risk

By LabMedica International staff writers
Posted on 31 May 2012
Elevated levels of HDL (high-density lipoprotein) cholesterol have long been recognized as a biomarker for reduced risk of heart disease, however data published in a recent paper found that drug treatment to raise levels of HDL cholesterol might not lower an individual’s heart attack risk.

Investigators at Harvard University Medical School (Boston, MA, USA) used a statistical approach based on “Mendelian randomization” to analyze nucleotide polymorphism (SNP) data from more than 170,000 individuals. More...
The SNPs were in genes linked to HDL metabolism. With such a large number of cases, individual variations evened out and any differences could be attributed to the specific SNPs under investigation.

Results published in the May 17, 2012, online edition of the journal the Lancet revealed that individuals carrying a particular variation in the gene for the enzyme endothelial lipase had HDL levels that were elevated by about six mg/dL, or 10% - representing a level of HDL cholesterol that would be expected to decrease heart attack risk by about 13%. However, this population showed no difference in risk of heart disease compared to those without the variant.

“It has been assumed that if a patient, or group of patients, did something to cause their HDL levels to go up, then you can safely assume that their risk of heart attack will go down,” said senior author Dr. Sekar Kathiresan, associate professor of medicine at Harvard Medical School. “This work fundamentally questions that. We know that HDL is a great biomarker – it is quite useful in identifying individuals at higher risk of having a heart attack in the future. But we have shown that you cannot assume that raising HDL by any mechanism will help patients. Perhaps other mechanisms exist that can lower risk, but we will need to keep searching for them.”

Related Links:

Harvard University Medical School



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Urine Analyzer
respons® UDS100
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.